QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.
Real-world evidence & analytics
Quantify is the leading provider of RWE generated from the world-renouned Nordic data. Through our local presence, expert staff, institutional know-how and more than 10 years’ hands-on experience with the Nordic data, we offer an unparalleled ability to advise and execute Nordic RWE studies with local and global applications. Quantify has a successful track record of advising clients on securing Nordic ethical approval, data access, and optimizing analysis for commercial or regulatory purposes. We also offer RWE services in the EU, UK, and US.
Modelling, Access & Strategy
Quantify is a global provider of health economic evidence and a specialist provider of Nordic market access services including economic models, reimbursement dossiers, and strategic advice. Our experience and expertise ensures an optimized, streamlined market access process across the Nordics. For non-technical stakeholders, Quantify also develops value tools and visualisation dashboards to enhance communication. Our expert staff include ex-payers, ex-pharma, modelling experts, and experienced project managers.
Evidence review & synthesis
Quantify has long standing experience reviewing, interpreting and communicating evidence as part of targeted or systematic literature reviews (SLR). Our team ensures these activities are done systematically, with a focus on usability, to support knowledge management and commercialization activities. QUANTIFY is experienced in summarizing the results of this work through meta-analyses and narrative reviews. Our team consists of 50% PhDs and integrated AI solutions to provide our clients with the very best services.
Press
Analyses From BISCUITS, a Large Nordic Observational Cohort Study
The poster “Healthcare Resource Use and Treatment Patterns in Patients With Difficult-to-Treat Osteoarthritis in Sweden: Analyses From ‘BISCUITS’, a Large Nordic Observational Cohort Study”, co-authored by Quantify’s Johan Liseth Hansen, describes the treatment patterns for NSAIDs and opioids in Swedish patients with a diagnosis of #osteoartritis (OA), including subgroups of patients defined as difficult-to-treat.
The findings, combined with other learnings from the BISCUITS study, create […]
Abstract co-authored by Quantify’s E. Toresson Grip presented at Heart Failure 2021 Online Congress
An abstract co-authored by Quantify’s Emilie Toresson Grip, has been accepted for oral presentation at the European Society of Cardiology Heart Failure 2021 Online Congress in June. For this abstract, called “Empagliflozin use versus dipeptidyl peptidase 4 inhibitors reduces risk of cardiovascular and renal disease among type 2 diabetes patients in routine care in Europe and Israel: EMPRISE study results”, the Quantify […]
Quality of Life in Patients with Osteoarthritis
The poster “Quality of Life in Patients with Osteoarthritis from Sweden; a Cohort Analysis from the ‘BISCUITS’ Study”, co-authored by Quantify’s Sara Hallberg, highlights the humanistic burden of #osteoarthritis (OA). With results showing that almost 80% of patients reported walking difficulties due to pain, the study confirms that patients with OA in Sweden experience a significant impact on their quality of life. Follow the […]
Quantify’s Douglas Knutsson interviewed by Life-time
Quantify’s Douglas Knutsson was interviewed by Life-time for having mapped the availability of 116 new medicines approved by the EMA in 2017-2019, on behalf of Lif – de forskande läkemedelsföretagen. The study covered not only the rate of availability and time to market but also factors affecting these parameters, an assessment of replaceability of non-available medicines and characteristics of medicines that were […]